Want to join the conversation?
$REGN, which competes with $AMGN & Novartis AG, said that 4Q15 EYLEA US net sales grew 44% YoverY to $746MM. The market share of treated eyes for EYLEA and DME is roughly double that of ranibizumab and similar to that for off-label bevacizumab. Praluent net sales were $7MM, which understates actual physician and patient demand.
$AAL is giving pay hikes to its employees but investors are sulking.
$APC stock tumbled more than 5.6% after last week's fatal home explosion in Firestone, Colorado prompted the company to close more than 3,000 wells for weeks.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.